BANK VONTOBEL/CALL/MODERNA/125/0.1/20.09.24 | Delayed Deutsche Boerse AG 16:03:00 27/06/2024 BST | ||
| 1.01 EUR | -15.83% |
|
| Current month | -51.81% | ||
| 1 month | -73.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 1.01 | -15.83% |
| 26/06/24 | 1.2 | -40.30% |
| 25/06/24 | 2.01 | +2.55% |
| 24/06/24 | 1.96 | +5.95% |
| 21/06/24 | 1.85 | -2.12% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 04:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VM7NK2 |
| ISIN | DE000VM7NK26 |
| Date issued | 29/12/2023 |
| Strike | 125 $ |
| Maturity | 20/09/2024 (85 Days) |
| Parity | 10 : 1 |
| Emission price | 1.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.59 € |
|---|---|
| Lowest since issue | 0.43 € |
| Spread | 0.02 € |
| Spread % | 1.79% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4
USD
Average target price
145.9
USD
Spread / Average Target
+19.11%
- Stock Market
- Warrants
- Warrant
